Fig. 7

Immune−related scores revealed different immunotherapy benefits in high− and low−CERPI groups. A The high−CERPI group demonstrated elevated stromal scores compared to the low−CERPI group; B Within the high−CERPI group, patients exhibited heightened TIDE and immune exclusion scores; C The TIDE algorithm was further employed to predict patient responses to immune checkpoint blockade therapy, revealing a higher proportion of responders in the low−CERPI group; D The low−CERPI patients had a higher IPS after receiving PD−1, PD−L1, PD−L2, and CTLA−4 monotherapy or combination therapy; E HE staining of slides from patients in TCGA−CRC cohort showed more immune cells infiltration around tumor cells in low−CERPI patients than in high−CERPI patients. ns p > 0.05; *p < 0.05; ***p < 0.001